Simvastatin (Zocor) Therapy in Sickle Cell Disease
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Recent clinical and experimental data indicate that statins have effects beyond cholesterol
lowering that may be beneficial in sickle cell disease by protecting the vascular
endothelium. Statins have been shown to attenuate endothelial dysfunction through their
anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II
dose-escalating trial is designed to assess the safety and potential clinical efficacy of
oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland UCSF Benioff Children's Hospital Oakland
Collaborators:
Department of Health and Human Services FDA Office of Orphan Products Development